▶ 調査レポート

糖尿病治療薬の世界市場分析・規模・シェア・成長・動向・予測:療法別、疾患別、流通経路別

• 英文タイトル:Diabetes Drugs Market (Therapy - Glucagon-like Peptide-1 (GLP-1) Agonist, Dipeptidyl-peptidase-4 (DPP-4) Inhibitors, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors, and Insulin; Disease Type - Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Impaired Glucose Tolerance and Impaired Fasting Glycaemia; By Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Transparency Market Researchが調査・発行した産業分析レポートです。糖尿病治療薬の世界市場分析・規模・シェア・成長・動向・予測:療法別、疾患別、流通経路別 / Diabetes Drugs Market (Therapy - Glucagon-like Peptide-1 (GLP-1) Agonist, Dipeptidyl-peptidase-4 (DPP-4) Inhibitors, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors, and Insulin; Disease Type - Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Impaired Glucose Tolerance and Impaired Fasting Glycaemia; By Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025 / TPM-B04114資料のイメージです。• レポートコード:TPM-B04114
• 出版社/出版日:Transparency Market Research / 2017年12月
• レポート形態:英文、PDF、223ページ
• 納品方法:Eメール
• 産業分類:製薬・医療
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Global Site License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、糖尿病治療薬の世界市場について調べ、糖尿病治療薬の世界規模、市場動向、市場環境、療法別分析、疾患別分析、流通経路別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、バリューチェーン分析、価格動向分析、関連企業情報などをまとめた調査レポートです。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・糖尿病治療薬の世界市場動向
・糖尿病治療薬の世界市場環境
・糖尿病治療薬のバリューチェーン分析
・糖尿病治療薬の価格動向分析
・糖尿病治療薬の世界市場規模
・糖尿病治療薬の世界市場規模:療法別
・糖尿病治療薬の世界市場規模:疾患別
・糖尿病治療薬の世界市場規模:流通経路別
・糖尿病治療薬の世界市場:地域別市場規模・分析
・糖尿病治療薬の北米市場規模・予測
・糖尿病治療薬のアメリカ市場規模・予測
・糖尿病治療薬の中南米市場規模・予測
・糖尿病治療薬のヨーロッパ市場規模・予測
・糖尿病治療薬のアジア市場規模・予測
・糖尿病治療薬の日本市場規模・予測
・糖尿病治療薬の中国市場規模・予測
・糖尿病治療薬のインド市場規模・予測
・糖尿病治療薬の中東市場規模・予測
・糖尿病治療薬のアフリカ市場規模・予測
・競争状況・関連企業情報

Global Diabetes Drugs Market: Snapshot

This report on the Diabetes drugs market analyzes the current and future scenario of the global market. Rise in private and public funding for diabetes drugs, rising prevalence of diabetes, and favorable regulatory scenario for new drug launch are boosting the growth of the Diabetes drugs market. Increasing geriatric population across the world and rising incidence and prevalence of diabetes such as Type 2 diabetes and Type 1 diabetes are some of the factors expected to drive the growth of Diabetes drugs market during the forecast period.

The diabetes drugs market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on therapy, disease type, distribution channel and geography. A detailed qualitative analysis of drivers and restraints, opportunities and trends have been provided in the market overview section. Additionally, the section comprises Porter’s Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the Diabetes drugs market.

Global Diabetes Drugs Market: Segmentation

Based on the therapy, the Diabetes drugs market has been segmented into 5 types, which are Glucagon-like peptide-1 (GLP-1) agonist, Dipeptidyl-peptidase-4 (DPP-4) inhibitors, Sodium glucose co-transporter 2 (SGLT2) inhibitors, Insulin and others. . The insulin dominated the market in terms of revenue in 2016, due to its high price, and need & demand for insulin. Insulin is expected to lead the market in the forecast period, owing to the rising geriatric population and high per capita income. SGLT2 is anticipated to grow during the forecast period owing to patents and exclusivity held for the drugs of this segment by the key players. The others segment includes the combination drugs and other drug classes are anticipated to grow during the forecast period 2017 to 2025. The Glucagon-like peptide-1 (GLP-1) agonist is anticipated to grow during the forecast period owing to rising prevalence of diabetes all over the world.Dipeptidyl-peptidase-4 (DPP-4) inhibitors held second large market share in 2016, however, the segment is anticipated to fall in the growth rate during the forecast period due to patent and exclusivity expiry.

In terms of disease type, the diabetes drugs market has been segmented into type 1 diabetes, type 2 diabetes, gestational diabetes, and impaired glucose tolerance and impaired fasting glycaemia. Type 2 diabetes has accounted for highest market share due to increasing disposable income and rising prevalence of obesity. Increasing physical inactivity created demand for the diabetes drugs. Type 1 diabetes held the second large market share in 2016 owing to increasing environmental damage all over the world that is contributing to the rising prevalence of type 1 diabetes. Gestational diabetes and impaired glucose tolerance and impaired fasting glycaemia are anticipated to grow during the forecast period 2017 to 2025 due to the high prevalence of diabetes in the relatives and heredity reason.

Different types of distribution channels are present in the diabetes drugs market those are Hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies captured highest market share in 2016, owing to the availability of trained & qualified personnel and favorable reimbursement structure. The online pharmacies is estimated to register highest CAGR in the forecast period, which is attributed to the technological adaptation and acceptance of online pharmacies by population. The retail pharmacies showed the moderate market share in 2016 owing to rising geriatric population & improvements in the healthcare facilities in developing countries are anticipated to propel the popularity of retail pharmacies during the forecast period. However, uncertain reimbursement scenarios across the world are attributed to restrain the diabetes drugs market to some extent during the forecast period.

Global Diabetes Drugs Market: Regional Segmentation

Geographically, the diabetes drugs Market has been categorized into five major regions and the key countries in the respective region: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, Japan, China, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa).

Global Diabetes Drugs Market: Competitive Landscape

The report also profiles major players in the Diabetes drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Novo Nordisk A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim GmbH, Sanofi, Bayer AG, Johnson & Johnson, Eli Lilly and Company, and Takeda Pharmaceutical Company Limited.

Diabetes Drugs Market has been segmented as given below:

Diabetes Drugs Market, by Therapy

Glucagon-like peptide-1 (GLP-1) agonist
Dipeptidyl-peptidase-4 (DPP-4) inhibitors
Sodium glucose co-transporter 2 (SGLT2) inhibitors
Insulin
Others
Diabetes Drugs Market, by Disease Type

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Impaired Glucose Tolerance and Impaired Fasting Glycaemia
Diabetes Drugs Market, by Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Diabetes Drugs Market, by Geography

North America
U.S.
Canada
Europe
Germany
France
Italy
Spain
UK
Rest of Europe
Asia Pacific
China
Japan
India
Australia & New Zealand
Rest of Asia Pacific
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Mexico
Rest of Latin America

レポート目次

1. Preface
1.1. Market Segmentation
1.2. Key Research Objectives
1.3. Research Highlights

2. Assumptions and Research Methodology
2.1. Secondary Research Methodology
2.2. Primary Research Methodology
2.3. Analysis Research Methodology
2.4. Final Report & Conclusions Research Methodology

3. Executive Summary: Global Diabetes Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Therapy Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Key Market Indicators
4.3.1. Region/Country Specific
4.3.2. Product/Application/Technology Specific
4.3.3. Target Market Specific – Global Scenario
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.4.3. Opportunity Analysis
4.4.4. Trends
4.5. Global Diabetes Drugs Market Analysis and Forecasts, 2015–2025
4.6. Porter’s Five Forces Analysis
4.7. Value Chain Analysis
4.8. Pipeline Analysis

5. Global Diabetes Drugs Market Analysis and Forecasts, By Therapy
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Forecast by Therapy, 2015–2025
5.4.1. Glucagon-like peptide-1 (GLP-1) agonist
5.4.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
5.4.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
5.4.4. Insulin
5.4.5. Others
5.5. Market Attractiveness by Therapy

6. Global Diabetes Drugs Market Analysis and Forecasts, By Disease Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value Forecast by Disease Type, 2015–2025
6.4.1. Type 1 Diabetes
6.4.2. Type 2 Diabetes
6.4.3. Gestational Diabetes
6.4.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
6.5. Disease Type Comparison Matrix
6.6. Market Attractiveness by Disease Type

7. Global Diabetes Drugs Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Value Forecast by Distribution Channel, 2015–2025
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Online Pharmacies
7.5. Distribution Channel Comparison Matrix
7.6. Market Attractiveness by Distribution Channel

8. Global Diabetes Drugs Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Policies and Regulations
8.3. Market Value Forecast by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Middle East & Africa
8.3.5. Latin America
8.4. Market Attractiveness by Country/Region

9. North America Diabetes Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Policies and Regulations
9.1.3. Price Trend Analysis
9.1.4. Key Trends
9.2. Market Value Forecast by Therapy, 2015–2025
9.2.1. Glucagon-like peptide-1 (GLP-1) agonist
9.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
9.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
9.2.4. Insulin
9.2.5. Others
9.3. Market Value Forecast by Disease Type, 2015–2025
9.3.1. Type 1 Diabetes
9.3.2. Type 2 Diabetes
9.3.3. Gestational Diabetes
9.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
9.4. Market Value Forecast by Distribution Channel, 2015–2025
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Market Value Forecast by Country, 2015–2025
9.5.1. U. S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. by Therapy
9.6.2. by Disease Type
9.6.3. by Distribution Channel
9.6.4. by Country
9.7. Key Trends

10. Europe Diabetes Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Price Trend Analysis
10.1.4. Key Trends
10.2. Market Value Forecast by Therapy, 2015–2025
10.2.1. Glucagon-like peptide-1 (GLP-1) agonist
10.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
10.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
10.2.4. Insulin
10.2.5. Others
10.3. Market Value Forecast by Disease Type, 2015–2025
10.3.1. Type 1 Diabetes
10.3.2. Type 2 Diabetes
10.3.3. Gestational Diabetes
10.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
10.4. Market Value Forecast by Distribution Channel, 2015–2025
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast by Country, 2015–2025
10.5.1. Germany
10.5.2. France
10.5.3. Italy
10.5.4. Spain
10.5.5. UK
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. by Therapy
10.6.2. by Disease Type
10.6.3. by Distribution Channel
10.6.4. by Country
10.7. Key Trends

11. Asia Pacific Diabetes Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.1.3. Price Trend Analysis
11.1.4. Key Trends
11.2. Market Value Forecast by Therapy, 2015–2025
11.2.1. Glucagon-like peptide-1 (GLP-1) agonist
11.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
11.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
11.2.4. Insulin
11.2.5. Others
11.3. Market Value Forecast by Disease Type, 2015–2025
11.3.1. Type 1 Diabetes
11.3.2. Type 2 Diabetes
11.3.3. Gestational Diabetes
11.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
11.4. Market Value Forecast by Distribution Channel, 2015–2025
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast by Country, 2015–2025
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. by Therapy
11.6.2. by Disease Type
11.6.3. by Distribution Channel
11.6.4. by Country
11.7 Key Trends

12. Middle East & Africa Diabetes Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Policies and Regulations
12.1.3. Price Trend Analysis
12.1.4. Key Trends
12.2. Market Value Forecast by Therapy, 2015–2025
12.2.1. Glucagon-like peptide-1 (GLP-1) agonist
12.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
12.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
12.2.4. Insulin
12.2.5. Others
12.3. Market Value Forecast by Disease Type, 2015–2025
12.3.1. Type 1 Diabetes
12.3.2. Type 2 Diabetes
12.3.3. Gestational Diabetes
12.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
12.4. Market Value Forecast by Distribution Channel, 2015–2025
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast by Country, 2015–2025
12.5.1. GCC Countries
12.5.2. South Africa
12.5.3. Rest of Middle East & Africa
12.6. Market Attractiveness Analysis
12.6.1. by Therapy
12.6.2. by Disease Type
12.6.3. by Distribution Channel
12.6.4. by Country
12.7. Key Trends

13. Latin America Diabetes Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.1.2. Policies and Regulations
13.1.3. Price Trend Analysis
13.1.4. Key Trends
13.2. Market Value Forecast by Therapy, 2015–2025
13.2.1. Glucagon-like peptide-1 (GLP-1) agonist
13.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
13.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
13.2.4. Insulin
13.2.5. Others
13.3. Market Value Forecast by Disease Type, 2015–2025
13.3.1. Type 1 Diabetes
13.3.2. Type 2 Diabetes
13.3.3. Gestational Diabetes
13.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
13.4. Market Value Forecast by Distribution Channel, 2015–2025
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast by Country, 2015–2025
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. by Therapy
13.6.2. by Disease Type
13.6.3. by Distribution Channel
13.6.4. by Country
13.7. Key Trends

14. Competition Landscape
14.1. Competition Matrix
14.2. Market Share Analysis by Company (2015)
14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.3.1. Novo Nordisk A/S
14.3.1.1. Company Description
14.3.1.2. Financial Overview
14.3.1.3. Strategic Overview
14.3.1.4. Recent Developments
14.3.1.5. SWOT ANALYSIS
14.3.2. Sanofi
14.3.2.1. Company Description
14.3.2.2. Financial Overview
14.3.2.3. Strategic Overview
14.3.2.4. Recent Developments
14.3.2.5. SWOT ANALYSIS
14.3.3. Merck & Co., Inc.
14.3.3.1. Company Description
14.3.3.2. Financial Overview
14.3.3.3. Strategic Overview
14.3.3.4. Recent Developments
14.3.3.5. SWOT ANALYSIS
14.3.4. Eli Lilly and company
14.3.4.1. Company Description
14.3.4.2. Financial Overview
14.3.4.3. Strategic Overview
14.3.4.4. Recent Developments
14.3.4.5. SWOT ANALYSIS
14.3.5. AstraZeneca
14.3.5.1. Company Description
14.3.5.2. Financial Overview
14.3.5.3. Strategic Overview
14.3.5.4. Recent Developments
14.3.5.5. SWOT ANALYSIS
14.3.6. Boehringer Ingelheim GmbH
14.3.6.1. Company Description
14.3.6.2. Financial Overview
14.3.6.3. Strategic Overview
14.3.6.4. Recent Developments
14.3.6.5. SWOT ANALYSIS
14.3.7. Johnson & Johnson
14.3.7.1. Company Description
14.3.7.2. Financial Overview
14.3.7.3. Strategic Overview
14.3.7.4. Recent Developments
14.3.7.5. SWOT ANALYSIS
14.3.8. Novartis AG
14.3.8.1. Company Description
14.3.8.2. Financial Overview
14.3.8.3. Strategic Overview
14.3.8.4. Recent Developments
14.3.8.5. SWOT ANALYSIS
14.3.9. Takeda Pharmaceutical Company Limited
14.3.9.1. Company Description
14.3.9.2. Financial Overview
14.3.9.3. Strategic Overview
14.3.9.4. Recent Developments
14.3.9.5. SWOT ANALYSIS
14.3.10. Bayer AG
14.3.10.1. Company Description
14.3.10.2. Financial Overview
14.3.10.3. Recent Developments
14.3.10.4. SWOT ANALYSIS

List of Tables

Table 1: Opportunity Map, 2016
Table 2: Opportunity Map, 2016
Table 3: Opportunity Map, 2016
Table 4: Pipeline Analysis, By Phase 3 Drugs
Table 5: Pipeline Analysis, By Phase 2 (1/2)
Table 6: Pipeline Analysis, by phase 2 (2/2)
Table 7: Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Therapy, 2015–2025
Table 8: Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 9: Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 10: Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 11: North America Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy, 2015–2025
Table 12: North America Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 13: North America Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 14: North America Diabetes Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 15: Europe Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy, 2015–2025
Table 16: Europe Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 17: Europe Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 18: Europe Diabetes Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 19: Asia Pacific Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy, 2015–2025
Table 20: Asia Pacific Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 21: Asia Pacific Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 22: Asia Pacific Diabetes Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 23: Middle East & Africa Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy,
Table 24: Middle East & Africa Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 25: Middle East & Africa Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 26: Middle East & Africa Diabetes Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 27: Latin America Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy, 2015–2025
Table 28: Latin America Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 29: Latin America Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 30: Latin America Diabetes Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025